by Eric Christianson | Oct 12, 2025 | Cardiovascular Case Studies
In this case scenario, we will look at the importance of making an apixaban (podcast) dose adjustment based upon clinical factors. LS is an 83-year-old female with a history of atrial fibrillation, hypertension, and osteoarthritis. She’s currently prescribed Eliquis...
by Eric Christianson | Sep 14, 2025 | Drug Interaction Case Studies and Education For Pharmacists
SK is a 77-year-old male who presents to the primary care clinic for a routine follow-up. His past medical history is significant for atrial fibrillation, hypertension, GERD, and depression. Can you identify two important drug interactions in this medication list?...
by Eric Christianson | Feb 19, 2025 | Cardiovascular Medication and Disease State Clinical Pearls
Diltiazem and verapamil are two non-dihydropyridine calcium channel blockers (non-DHP CCBs) most commonly used in managing certain cardiac conditions. Even though they fall into the same medication class, these medications have important pharmacological differences...
by Eric Christianson | Dec 20, 2023 | Drug Interaction Case Studies and Education For Pharmacists
I recently came across a clinical issue in my practice as a consultant pharmacist to assisted living and long-term care facilities. The item in question was how to manage the apixaban diltiazem interaction. Apixaban Diltiazem Interaction Defined Apixaban is...
by Eric Christianson | Nov 1, 2023 | Cardiovascular Medication and Disease State Clinical Pearls
Calcium channel blockers (CCBs) are split into two categories, dihydropyridines (DHP), such as amlodipine and nicardipine, and non-dihydropyridines (non-DHP), such as verapamil and diltiazem. While these two drug classes are both CCBs, there are some key similarities...
